Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.47 |
| ▸ | DRD2 | P14416 | 9/20 | 0.47 |
| ▸ | DRD3 | P35462 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25358567 | 0.87 | SIGMAR1 (0.54) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL26012437 | 0.86 | DRD4 (0.55) | DRD4DRD2DRD3HTR2CMEN1 | |
| SCHEMBL26012148 | 0.86 | DRD4 (0.55) | DRD4DRD2DRD3HTR2CMEN1 | |
| SCHEMBL26013065 | 0.86 | MEN1 (0.44) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL25358283 | 0.86 | DRD4 (0.44) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL26012362 | 0.85 | MAPK1 (0.51) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL26013082 | 0.82 | DRD4 (0.51) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL26012483 | 0.78 | DRD4 (0.45) | DRD4DRD2DRD3HTR2CMEN1 | |
| SCHEMBL26013084 | 0.77 | DRD4 (0.46) | DRD4DRD2DRD3HTR2CHTR1A | |
| SCHEMBL26012261 | 0.76 | DRD4 (0.48) | DRD4DRD2DRD3HTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |